Neurology Department, Movement Disorder Unit, [corrected] La Paz University Hospital, Paseo Castellana 261, Madrid, Spain.
Int J Neurosci. 2012 Jul;122(7):354-7. doi: 10.3109/00207454.2012.665971. Epub 2012 Mar 20.
To investigate the long-term efficacy and safety of a botulinum toxin type A (BoNT-A) for the treatment of cervical dystonia (CD).
We conducted a retrospective chart review of patients with CD treated with abobotulinumtoxinA (Dysport™ 100-800 units [U] for injection) between 1993 and 2009 at the University Hospital "La Paz" (LPUH). Affected muscles were selected using electromyography (EMG).
Thirty-seven patients were included in the study; most were female (62%) and had idiopathic CD (60%). Almost half (46%) of patients were diagnosed with the condition more than 10 years ago. The most common clinical presentations of CD were rotation (46%) and laterocollis (43%). On average, patients were treated with Dysport for 7 years (range: 1-17 years) and received 487 (range: 320 to 650) U over 15.9 (range: 1 to 40) injection cycles. Most (97%) patients maintained a response from treatment initiation to end of evaluation period. Overall, 70% of patients were taking concomitant oral medication. Dysport was generally well tolerated. Dysphagia was reported by 18.9% of patients, but this did not lead to discontinuation of Dysport treatment.
These data confirm the long-term efficacy and safety of Dysport in CD over a period of up to 17 years.
研究 A 型肉毒毒素（BoNT-A）治疗颈肌张力障碍（CD）的长期疗效和安全性。
我们对 1993 年至 2009 年期间在拉·帕斯大学医院（LPUH）接受 abobotulinumtoxinA（Dysport™ 100-800 单位[U]注射）治疗的 CD 患者进行了回顾性图表审查。使用肌电图（EMG）选择受影响的肌肉。
37 例患者纳入研究；大多数为女性（62%），患有特发性 CD（60%）。近一半（46%）的患者在 10 年前被诊断出患有该疾病。CD 最常见的临床表现为旋转（46%）和斜颈（43%）。平均而言，患者接受 Dysport 治疗 7 年（范围：1-17 年），共接受 487（范围：320 至 650）U，共进行 15.9（范围：1 至 40）次注射。大多数（97%）患者从治疗开始到评估结束都保持反应。总体而言，70%的患者同时服用口服药物。Dysport 通常耐受性良好。18.9%的患者报告出现吞咽困难，但这并未导致 Dysport 治疗中断。
这些数据证实了 Dysport 在长达 17 年的时间内治疗 CD 的长期疗效和安全性。
